FDA approves pembrolizumab as first-line treatment for lung cancer

Ryan Maass
WASHINGTON, Oct. 26 (UPI) -- The U.S. Food and Drug Administration has approved pembrolizumab, sold as Keytruda, as a first-line lung cancer treatment alternative to chemotherapy.